Biomarkers for Traumatic Brain Injury

Dr. Alan Wu is a Professor of Laboratory Medicine at the University of California at San Francisco. He is the Co-Director of the Core Laboratory at the Zuckerberg San Francisco General Hospital. His research is focused on biomarkers of cardiovascular disease, clinical toxicology, and pharmacogenomics. In this capacity, his clinical and research laboratory conducts testing for routine analytes in blood, urine and cerebral spinal fluid for electrolytes, metabolites, hormones, proteins, and biomarkers. His particular area of interest is in cardiac biomarkers for acute cardiac diseases. He received a B.S. in both Chemistry and Biology at Purdue University and a Ph.D. in Analytical Chemistry at the University of Illinois. He was a professor at the University of Texas and the University of Connecticut prior to his current position at UCSF. W. Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine and Vice Chair for Research in the department of Emergency Medicine at Baylor College of Medicine, in Houston, Texas. He has >500 publications, is a two-time winner of the Best Research Paper of the Year Award from the American College of Emergency Physicians, and the 2019 Ray Bahr Award for Excellence from the American College of Cardiology. Finally, he is the founder of Comprehensive Research Associates, LLC, and Emergencies in Medicine, LLC.

"This book does a satisfactory job of serving as an introductory reference on traumatic brain injury and associated biomarkers available or in the works. My preferred reference is Textbook of Traumatic Brain Injury, 3rd edition, Silver et al. (American Psychiatric Association Publishing, 2019,) both for its breadth and detailed information. Brain Injury Medicine: Principles and Practice, 2nd edition, Zasler et al. (Springer Publishing Company, 2013) is also a good alternative. Although these two do not strictly cover TBI, they have better organization, more comprehensive information, and better readability." --Doody

• Section I. INTRODUCTION1. Introduction—scope of the problem2. The need for traumatic brain injury markers3. Regulatory considerations for diagnostics and biomarkers of traumatic brain injury Section II. PATHOPHYSIOLOGY OF TBI4. Peripheral markers of TBI and blood-brain barrier disruption5. The role of autoimmunity after traumatic brain injury6. Traumatic brain injury: glial fibrillary acidic protein posttranslationalmodificationSECTION III. TBI BIOMARKERS IN MEDICAL PRACTICE7. Economics of traumatic brain injury biomarkers8. Electrophysiology monitoring9. Traumatic brain injury therapeuticsSECTION IV. CLASSICAL TBI BIOMARKERS10. S100 biomarkers in patients with traumatic brain injury11. Pathophysiology and clinical implementation of traumatic brain injury biomarkers: neuron-specific enolase12. Traumatic brain injury biomarkers glial fibrillary acidic protein/ubiquitin C-terminal hydrolase L113. Neurofilaments light chain/Neurofilaments heavy chain14. Tau protein, biomarker for traumatic brain injurySECTION V. NOVEL TBI BIOMARKERS15. Neurogranin16. Myelin basic protein in traumatic brain injurySECTION VI. ANALYTICAL TESTING CONSIDERATION17. Antibody selection, evaluation, and validation for analysis of traumatic brain injury biomarkers18. Sensitive immunoassay testing platforms19. Clinical mass spectrometry and its applications in traumatic brain injuries20. Surface plasmon resonance21. Point-of-care testing for concussion and traumatic brain injurySECTION VII. NON-BLOOD TBI BIOMARKER STRATEGY22. Clinical risk factors of traumatic brain injury23. Saliva biomarkers of traumatic brain injury24. Digital neurocognitive testing25. Electroencephalographic as a biomarker of concussion 26. Neuropsychological testing27. Outpatient risk stratification for traumatic brain injury28. Peptidomics and traumatic brain injury: biomarker utilities for a theragnostic approach29. Autoantibodies in central nervous system trauma: new frontiers for diagnosis and prognosis biomarkers